{"id":791282,"date":"2024-11-29T09:46:49","date_gmt":"2024-11-29T14:46:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\/"},"modified":"2024-11-29T09:46:49","modified_gmt":"2024-11-29T14:46:49","slug":"correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\/","title":{"rendered":"CORRECTION: RadNet\u2019s DeepHealth Subsidiary Expands FDA Clearance for SmartMammo\u2122 Solution"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:left\">\n          <em>SmartMammo\u2122\u2019s AI algorithm now FDA cleared with GE HealthCare\u2019s Senographe Pristina\u2122, expanding access to enhanced cancer detection.<\/em>\n        <\/li>\n<\/ul>\n<ul type=\"disc\">\n<li>\n          <em>The clearance enables RadNet\u2019s DeepHealth and GE HealthCare collaboration to bring together the SmartMammo and Senographe Pristina solutions and transform breast cancer diagnosis.<\/em><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"left\">SOMERVILLE, Mass., Nov.  29, 2024  (GLOBE NEWSWIRE) &#8212; In a release issued under the same headline on Friday, November 29th by RadNet, Inc. (NASDAQ: RDNT), please note that in the third sentence of the first paragraph, the year that SmartMammo Dx was first cleared should be 2021, not 2012. The corrected release follows:<\/p>\n<p align=\"left\">DeepHealth, Inc., a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and a global leader in AI-powered health informatics, has received expanded FDA 510(k) clearance for its innovative mammography software. SmartMammo Dx, the AI algorithm within SmartMammo<sup>1<\/sup>, is now FDA-cleared to be compatible with GE HealthCare\u2019s Senographe Pristina\u2122 mammography systems. SmartMammo Dx was first cleared in May\u00a02021 in conjunction with HOLOGIC mammography systems, where its performance has also been tested and cleared in patients with unilateral breasts and with breast implants. This newly expanded clearance advances DeepHealth\u2019s mission to enhance and expand breast cancer screening programs by broadening system compatibility.<\/p>\n<p align=\"left\">\u201c<em>This FDA clearance allows us to expand access to high-quality breast cancer screening to more patients,<\/em>\u201d said Kees Wesdorp, President and CEO of RadNet\u2019s Digital Health segment. \u201c<em>By bringing SmartMammo\u2019s improved cancer detection to GE HealthCare\u2019s mammography systems, more providers can harness the power of AI to help redefine radiology workflows and address key challenges across the imaging value chain, to improve speed, clinical accuracy, operational efficiency, and elevate patient care.\u201d<\/em><\/p>\n<p align=\"left\">SmartMammo Dx is a key component of DeepHealth\u2019s comprehensive SmartMammo<sup>1<\/sup> solution, delivering advanced AI-driven tools that empower radiologists to interpret digital breast tomosynthesis (DBT) mammograms with greater precision. The software identifies suspicious soft tissue lesions and calcifications and assigns finding-specific and case-specific suspicion levels with increased diagnostic accuracy.<\/p>\n<p align=\"left\">DeepHealth\u2019s FDA-cleared breast cancer diagnostic technologies have already supported millions of exams over the last two years with HOLOGIC mammography systems through the Enhanced Breast Cancer Detection (EBCD) program at RadNet. The expanded FDA clearance with GE HealthCare\u2019s Senographe Pristina should further accelerate the adoption of AI-powered breast cancer screening at RadNet and with other providers.<\/p>\n<p align=\"left\">The FDA clearance underscores DeepHealth and GE HealthCare\u2019s shared commitment to advancing patient-centric, interoperable, and scalable imaging solutions. The two companies aim to set new standards in AI-powered breast imaging to help radiologists deliver better care faster.<\/p>\n<p align=\"left\">For more information about SmartMammo Dx and its impact on breast cancer screening, visit deephealth.com<\/p>\n<p align=\"left\">\n        <sup>1<\/sup> SmartMammo\u2122 comprises multiple components, including SmartMammo Dx (also known as Saige DX), SmartMammo Density, DeepHealth Viewer, and SmartMammo Assure. DeepHealth Viewer is Manufactured by eRAD and Distributed by DeepHealth. Any claims made about SmartMammo\u2122 may reference claims associated with its individual components.<\/p>\n<p align=\"left\">\n        <strong>About RadNet, Inc.<\/strong><br \/>\n        <br \/>RadNet, Inc. is the leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 399 owned and\/or operated outpatient imaging centers. RadNet\u2019s markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with affiliated radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 10,000 employees. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7aVwwg7ilOXhWJpAh8K69llnJk-Ia8_ePbH6e8PRNCd-_xtQhFQgwAHVnnlZ7VqBf9ptXOgeDbhoNmp65rdGqJD2OvWH22vuVHUVso5L9Uc=\" rel=\"nofollow\" target=\"_blank\"><u>http:\/\/www.radnet.com<\/u><\/a>.<\/p>\n<p align=\"left\">\n        <strong>About DeepHealth<\/strong><br \/>\n        <br \/>DeepHealth is a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for all companies within RadNet&#8217;s Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on\u00a0the strengths of the companies it has integrated and is rebranding (i.e., eRAD\u00a0Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence\u00a0lung AI, DeepHealth\u00a0and Kheiron breast AI and Quantib\u00a0prostate and brain AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth\u2019s portfolio is a cloud-native operating system &#8211; DeepHealth OS &#8211; that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth\u2019s\u00a0human-centered, intuitive technology aims to push the boundaries of what&#8217;s\u00a0possible in healthcare.\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0REBa7hgzLb3ExT4zLNLR4zhrCLqa5aS9KVqC7PtFsQFesSz5uozhhHcrHUORvppaDbLO19XuUihNP4aBaFbeHtOEfV4uP6J82QM9h9FzUU=\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/deephealth.com\/<\/u><\/a><\/p>\n<p align=\"left\">\n        <strong>Forward Looking Statement <\/strong><br \/>\n        <br \/>This press release contains \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements, including statements regarding the capabilities of RadNet, GE HealthCare, Hologic and DeepHealth\u2019s informatics, hardware and software product portfolios and the collaboration\u2019s impact on radiology practices and healthcare workflow, are expressions of our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cgoal,\u201d \u201cseek,\u201d \u201cbelieve,\u201d \u201cproject,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cstrategy,\u201d \u201cfuture,\u201d \u201clikely,\u201d \u201cmay,\u201d \u201cshould,\u201d \u201cwill\u201d and similar references to future periods.<\/p>\n<p align=\"left\">Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements.<\/p>\n<p align=\"left\">\n        <strong>For media inquiries, reach out to:<\/strong>\n      <\/p>\n<p align=\"left\">\n        <strong>DeepHealth<\/strong><br \/>\n        <br \/>Andra Axente<br \/>Communications Director<br \/>Phone: +31 614 440971<br \/>Email: andra.axente@deephealth.com<\/p>\n<p align=\"left\">\n        <strong>RadNet, Inc.<\/strong><br \/>\n        <br \/>Mark Stolper<br \/>Executive Vice President and Chief Financial Officer<br \/>310-445-2800<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTc3MCM2NjE2MDIyIzIwMDgwMTc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/M2JlMTQ4MjQtMDg2Ny00NWVhLWJhZDYtYmE0ZTNkM2E4MTYyLTEwMTk1OTA=\/tiny\/RadNet-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SmartMammo\u2122\u2019s AI algorithm now FDA cleared with GE HealthCare\u2019s Senographe Pristina\u2122, expanding access to enhanced cancer detection. The clearance enables RadNet\u2019s DeepHealth and GE HealthCare collaboration to bring together the SmartMammo and Senographe Pristina solutions and transform breast cancer diagnosis. SOMERVILLE, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) &#8212; In a release issued under the same headline on Friday, November 29th by RadNet, Inc. (NASDAQ: RDNT), please note that in the third sentence of the first paragraph, the year that SmartMammo Dx was first cleared should be 2021, not 2012. The corrected release follows: DeepHealth, Inc., a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and a global leader in AI-powered health informatics, has received expanded FDA 510(k) clearance for its innovative &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CORRECTION: RadNet\u2019s DeepHealth Subsidiary Expands FDA Clearance for SmartMammo\u2122 Solution&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-791282","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CORRECTION: RadNet\u2019s DeepHealth Subsidiary Expands FDA Clearance for SmartMammo\u2122 Solution - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CORRECTION: RadNet\u2019s DeepHealth Subsidiary Expands FDA Clearance for SmartMammo\u2122 Solution - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SmartMammo\u2122\u2019s AI algorithm now FDA cleared with GE HealthCare\u2019s Senographe Pristina\u2122, expanding access to enhanced cancer detection. The clearance enables RadNet\u2019s DeepHealth and GE HealthCare collaboration to bring together the SmartMammo and Senographe Pristina solutions and transform breast cancer diagnosis. SOMERVILLE, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) &#8212; In a release issued under the same headline on Friday, November 29th by RadNet, Inc. (NASDAQ: RDNT), please note that in the third sentence of the first paragraph, the year that SmartMammo Dx was first cleared should be 2021, not 2012. The corrected release follows: DeepHealth, Inc., a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and a global leader in AI-powered health informatics, has received expanded FDA 510(k) clearance for its innovative &hellip; Continue reading &quot;CORRECTION: RadNet\u2019s DeepHealth Subsidiary Expands FDA Clearance for SmartMammo\u2122 Solution&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-29T14:46:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTc3MCM2NjE2MDIyIzIwMDgwMTc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CORRECTION: RadNet\u2019s DeepHealth Subsidiary Expands FDA Clearance for SmartMammo\u2122 Solution\",\"datePublished\":\"2024-11-29T14:46:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\\\/\"},\"wordCount\":1002,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MTc3MCM2NjE2MDIyIzIwMDgwMTc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\\\/\",\"name\":\"CORRECTION: RadNet\u2019s DeepHealth Subsidiary Expands FDA Clearance for SmartMammo\u2122 Solution - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MTc3MCM2NjE2MDIyIzIwMDgwMTc=\",\"datePublished\":\"2024-11-29T14:46:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MTc3MCM2NjE2MDIyIzIwMDgwMTc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTI5MTc3MCM2NjE2MDIyIzIwMDgwMTc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CORRECTION: RadNet\u2019s DeepHealth Subsidiary Expands FDA Clearance for SmartMammo\u2122 Solution\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CORRECTION: RadNet\u2019s DeepHealth Subsidiary Expands FDA Clearance for SmartMammo\u2122 Solution - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\/","og_locale":"en_US","og_type":"article","og_title":"CORRECTION: RadNet\u2019s DeepHealth Subsidiary Expands FDA Clearance for SmartMammo\u2122 Solution - Market Newsdesk","og_description":"SmartMammo\u2122\u2019s AI algorithm now FDA cleared with GE HealthCare\u2019s Senographe Pristina\u2122, expanding access to enhanced cancer detection. The clearance enables RadNet\u2019s DeepHealth and GE HealthCare collaboration to bring together the SmartMammo and Senographe Pristina solutions and transform breast cancer diagnosis. SOMERVILLE, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) &#8212; In a release issued under the same headline on Friday, November 29th by RadNet, Inc. (NASDAQ: RDNT), please note that in the third sentence of the first paragraph, the year that SmartMammo Dx was first cleared should be 2021, not 2012. The corrected release follows: DeepHealth, Inc., a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and a global leader in AI-powered health informatics, has received expanded FDA 510(k) clearance for its innovative &hellip; Continue reading \"CORRECTION: RadNet\u2019s DeepHealth Subsidiary Expands FDA Clearance for SmartMammo\u2122 Solution\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\/","og_site_name":"Market Newsdesk","article_published_time":"2024-11-29T14:46:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTc3MCM2NjE2MDIyIzIwMDgwMTc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CORRECTION: RadNet\u2019s DeepHealth Subsidiary Expands FDA Clearance for SmartMammo\u2122 Solution","datePublished":"2024-11-29T14:46:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\/"},"wordCount":1002,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTc3MCM2NjE2MDIyIzIwMDgwMTc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\/","name":"CORRECTION: RadNet\u2019s DeepHealth Subsidiary Expands FDA Clearance for SmartMammo\u2122 Solution - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTc3MCM2NjE2MDIyIzIwMDgwMTc=","datePublished":"2024-11-29T14:46:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTc3MCM2NjE2MDIyIzIwMDgwMTc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTI5MTc3MCM2NjE2MDIyIzIwMDgwMTc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/correction-radnets-deephealth-subsidiary-expands-fda-clearance-for-smartmammo-solution\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CORRECTION: RadNet\u2019s DeepHealth Subsidiary Expands FDA Clearance for SmartMammo\u2122 Solution"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/791282","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=791282"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/791282\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=791282"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=791282"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=791282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}